UK Markets closed

Frequency Therapeutics, Inc. (FREQ)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.14+0.17 (+1.71%)
At close: 4:00PM EDT
9.90 -0.24 (-2.37%)
After hours: 05:03PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5346.98M
Enterprise value 3187.6M
Trailing P/E N/A
Forward P/E 1-4.90
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)9.38
Price/book (mrq)N/A
Enterprise value/revenue 35.07
Enterprise value/EBITDA 7-7.11

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 358.37
52-week low 37.34
50-day moving average 39.56
200-day moving average 326.99

Share statistics

Avg vol (3-month) 31.56M
Avg vol (10-day) 3343.88k
Shares outstanding 534.22M
Implied shares outstanding 6N/A
Float 26.26M
% held by insiders 112.35%
% held by institutions 164.46%
Shares short (14 Apr 2021) 46.08M
Short ratio (14 Apr 2021) 41.89
Short % of float (14 Apr 2021) 419.57%
Short % of shares outstanding (14 Apr 2021) 417.80%
Shares short (prior month 14 Mar 2021) 44.16M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Dec 2020


Profit margin -71.68%
Operating margin (ttm)-74.49%

Management effectiveness

Return on assets (ttm)-7.06%
Return on equity (ttm)-14.73%

Income statement

Revenue (ttm)36.98M
Revenue per share (ttm)1.15
Quarterly revenue growth (yoy)111.30%
Gross profit (ttm)36.98M
Net income avi to common (ttm)-26.51M
Diluted EPS (ttm)-10.29
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)220.34M
Total cash per share (mrq)6.45
Total debt (mrq)45.99M
Total debt/equity (mrq)23.89
Current ratio (mrq)8.45
Book value per share (mrq)-25.04

Cash flow statement

Operating cash flow (ttm)-45.19M
Levered free cash flow (ttm)-40.03M